|
Company
Roster
|
Total
Insiders : |
21 |
|
|
Total
Direct Shares :
|
135,512 |
|
Total
Indirect Shares :
|
18,762,386 |
|
%
Held by Insiders:
|
0.37% |
|
|
|
Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Howard Alvin D |
VP Regulatory |
2018-11-19 |
38,414 |
2018-01-01 |
0 |
Hazot Yohan |
VP Pharmaceutical Development |
2018-01-15 |
27,300 |
2018-01-01 |
0 |
Schuz David |
VP IP |
2018-01-15 |
19,980 |
2018-01-01 |
0 |
Shirvan Mitchell |
VP Innovation & Discovery |
2018-01-15 |
19,980 |
2018-01-01 |
0 |
Elliott Russell P. |
VP Drug Development |
2018-10-01 |
12,442 |
2018-01-01 |
0 |
Eini Meir |
Observer to the Board |
2018-01-15 |
17,396 |
2018-01-11 |
2,717,781 |
Schwartz Aharon |
Director |
2020-03-09 |
0 |
2018-11-26 |
0 |
Stern Stanley |
Director |
2020-03-09 |
0 |
2019-05-16 |
0 |
Kazanchyan Anna |
Director |
2020-03-09 |
0 |
2018-05-08 |
0 |
Hirsch Stanley |
Director |
2020-03-09 |
0 |
2020-03-09 |
59,016 |
Bruno Anthony D |
Director |
2020-03-09 |
0 |
2019-05-16 |
0 |
Harsch Mutya |
CLO and General Counsel |
2020-03-09 |
0 |
2019-01-01 |
0 |
Stuart Iain |
Chief Scientific Officer |
2020-03-09 |
0 |
2018-08-08 |
0 |
Wiley Matthew T. |
Chief Commercial Officer |
2020-03-09 |
0 |
2018-12-03 |
0 |
Hadar Ilan |
CFO & Country Manager |
2020-03-09 |
0 |
2018-01-01 |
0 |
Domzalski David |
CEO, Director |
2020-03-09 |
0 |
2018-01-01 |
0 |
Kroin David |
10% Owner |
|
0 |
2017-04-10 |
4,781,708 |
Edelman Joseph |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Megiddo Dalia |
|
|
0 |
|
0 |
Bright Rex |
|
|
0 |
|
0 |
Rigel Darrell S |
|
|
0 |
|
0 |
|